Rhythm Biosciences (FRA:0RY) Accumulated Depreciation: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0RY Rhythm Biosciences Ltd FRA:0RY
18 GF Score
Price €0.05
! 1 Warning Sign
View Full Analysis

What is Rhythm Biosciences Accumulated Depreciation?

Rhythm Biosciences FRA:0RY -3.92% 18 Accumulated Depreciation is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:0RY with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Rhythm Biosciences's annual accumulated depreciation declined from Jun. 2024 (€-0.21 Mil) to Jun. 2025 (€0.00 Mil) but then stayed the same from Jun. 2025 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).

Rhythm Biosciences Accumulated Depreciation Related Terms

Rhythm Biosciences Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Accumulated Depreciation Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only -0.14 -0.17 -0.21 0.00 0.00

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 0.00 0.00 0.00 0.00
FRA:0RY
18GF Score
Rhythm Biosciences Ltd FRA:0RY
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €0.00 Mil mean?
Rhythm Biosciences (FRA:0RY) has a Accumulated Depreciation of €0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' Accumulated Depreciation too high?
Rhythm Biosciences' current Accumulated Depreciation is €0.00 Mil. Overall, Rhythm Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Accumulated Depreciation compare to TMO and DHR?
Rhythm Biosciences' Accumulated Depreciation of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Diagnostics & Research company?
A good Accumulated Depreciation depends on the Medical Diagnostics & Research industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Accumulated Depreciation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Accumulated Depreciation of €0.00 Mil. The current Accumulated Depreciation is €0.00 Mil. Rhythm Biosciences' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Accumulated Depreciation is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
18GF Score

Get the complete analysis for FRA:0RY

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price